[Spontaneous thrombocyte aggregation in patients with ischemic cardiopathy. Effect of anti-aggregant treatment on thrombocyte function and other coagulation factors].
D001162:Arteriosclerosis Obliterans / Q000209:etiology*; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D002866:Chromonar / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications*; D004176:Dipyridamole / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias; D010974:Platelet Aggregation; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013923:Thromboembolism / Q000209:etiology*; D013927:Thrombosis / Q000209:etiology*
D004176:Dipyridamole; D002866:Chromonar; D001241:Aspirin; D013442:Sulfinpyrazone
L'agrégation thrombocytaire spontanée chez des malades avec cardiopathie ischémique. Influence du traitement antiagrégant sur la fonction thrombocytaire et les autres facteurs de la coagulation.